0IMT Stock Overview Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details
Rewards Risk Analysis No risks detected for 0IMT from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Photocure ASA Competitors Price History & Performance
Summary of share price highs, lows and changes for Photocure Historical stock prices Current Share Price NOK 63.80 52 Week High NOK 71.90 52 Week Low NOK 48.05 Beta 0.96 1 Month Change 30.34% 3 Month Change 22.22% 1 Year Change -4.06% 3 Year Change -35.95% 5 Year Change -20.25% Change since IPO 40.22%
Recent News & Updates
Photocure ASA, Annual General Meeting, May 05, 2025 Dec 13 Photocure ASA to Report Fiscal Year 2024 Results on Apr 11, 2025
Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023) Nov 16
Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023) Aug 08
New minor risk - Share price stability Aug 05
Photocure ASA Announces Board Appointments May 25 See more updates
Photocure ASA, Annual General Meeting, May 05, 2025 Dec 13 Photocure ASA to Report Fiscal Year 2024 Results on Apr 11, 2025
Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023) Nov 16
Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023) Aug 08
New minor risk - Share price stability Aug 05
Photocure ASA Announces Board Appointments May 25
First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023) May 17 Photocure ASA Reiterates Financial Guidance for the Year 2024 May 16
Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence Apr 30
Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy Mar 29
Full year 2023 earnings released: EPS: kr0.01 (vs kr2.66 loss in FY 2022) Feb 22
Forecast breakeven date pushed back to 2025 Feb 22 Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024
Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China Nov 29
Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022) Nov 09
Photocure ASA Announces Change of Board Composition Sep 28
Director recently bought kr6.5m worth of stock Sep 05
Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint Aug 12
Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.68 loss in 2Q 2022) Aug 10
Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China Jul 07
Insufficient new directors Jul 01
Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021) Apr 14
Forecast breakeven date pushed back to 2024 Feb 25
Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021) Feb 24
Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC Feb 20
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week Jan 05
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week Jan 04 Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023
Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy Dec 05
Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021) Nov 07
Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc Oct 06
PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S Sep 28
Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology Sep 20
Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy Sep 08
Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development Sep 01
Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021) Aug 11
Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States Jul 28
Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki Jun 13
Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022. Jun 04
First quarter 2022 earnings released: kr0.82 loss per share (vs kr0.57 profit in 1Q 2021) May 13
Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020) Apr 08
Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand Mar 06
Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model Feb 28
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S Feb 07
Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020) Nov 18
Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020) Aug 12
Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology Jun 25
Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira) Jun 22
Photocure ASA (OB:PHO) announces an Equity Buyback for 2,682,006 shares, representing 10% of its issued share capital. Jun 10
Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020. Mar 28
Photocure ASA Suspends Guidance for 2023 Mar 04 Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021
Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan Jan 28
Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan Jan 26
Photocure Announces New Cevira Patent In Europe Oct 06
Photocure Launches European Hexvix Operations Oct 03
Photocure ASA Provides Revenue Guidance for the Year 2020 Aug 19 Shareholder Returns 0IMT GB Pharmaceuticals GB Market 7D -0.2% 0.3% 0.4% 1Y -4.1% -4.4% 3.3%
See full shareholder returns
Return vs Market: 0IMT underperformed the UK Market which returned 2.3% over the past year.
Price Volatility Is 0IMT's price volatile compared to industry and market? 0IMT volatility 0IMT Average Weekly Movement 5.5% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0IMT has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0IMT's weekly volatility (6%) has been stable over the past year.
About the Company Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Show more Photocure ASA Fundamentals Summary How do Photocure's earnings and revenue compare to its market cap? 0IMT fundamental statistics Market cap NOK 1.68b Earnings (TTM ) NOK 14.16m Revenue (TTM ) NOK 526.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0IMT income statement (TTM ) Revenue NOK 526.25m Cost of Revenue NOK 29.11m Gross Profit NOK 497.15m Other Expenses NOK 482.98m Earnings NOK 14.16m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
Earnings per share (EPS) 0.52 Gross Margin 94.47% Net Profit Margin 2.69% Debt/Equity Ratio 0%
How did 0IMT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/01 14:24 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Photocure ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hans Bohn Beringer Finance AB null null Brookline Capital Markets Patrik Ling DNB Markets
Show 2 more analysts 
